Perspective Therapeutics, Inc. CATX
Set alert
At close · Oct 30
After hours · Oct 30, 5:53 PM ET
- YTD
- -58.18%
- 1 year
- -56.44%
- Open
- 1.12
- Prev close
- 1.17
- Mkt cap
- 131.27M
- Vol
- 2.31M
- Avg vol
- 2.02M
- EPS
- -1.33
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.09
- High
- 1.15
- Forward P/E
- -2.91
- Beta
- 1.47
- Short ratio
- 4.69
- Inst. own
- 81.43%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 7.97
- 200-d avg
- 12.20
- 1y target
- 16.15
3M chart
Signals (13)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 8, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 6, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 31, 2026 | 3 months ago |
Key statistics
- Market cap
- 212.22M
- Enterprise value
- -70.95M
- Trailing P/E
- 0.00
- Forward P/E
- -2.91
- PEG ratio
- 0.00
- Price / sales
- 136.30
- Price / book
- 0.65
- EPS (TTM)
- -1.33
- Beta
- 1.47
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.56M
- Revenue growth
- 33.70%
- Free cash flow
- -49.49M
- Total cash
- 267.85M
- Total debt
- 4.27M
- Return on equity
- -27.02%
- Shares outstanding
- 67.59M
- Short % of float
- 18.81%
- 50-day average
- 7.97
- 200-day average
- 12.20
Analyst view
Consensus: strong buy
- Target (low)
- 6.00
- Target (mean)
- 16.15
- Target (high)
- 21.00
- Strong buy1
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.25994.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | RBC Capital | main | Outperform | Outperform |
| Nov 25, 2024 | B of A Securities | down | Buy | Neutral |
| Nov 22, 2024 | Oppenheimer | main | Outperform | Outperform |
| Oct 24, 2024 | Wedbush | reit | Outperform | Outperform |
| Oct 24, 2024 | UBS | init | — | Buy |
| Oct 11, 2024 | Oppenheimer | reit | Outperform | Outperform |
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- perspectivetherapeutics.com
News
- RBC Capital Downgrades Perspective Therapeutics to Sector Perform, Lowers Price Target to $4
- Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
- Perspective Therapeutics Announces Interim Data From Its Current Phase 1/2a Clinical Study Of [212Pb]VMT-α-NET In Patients With Unresectable Or Metastatic Somatostatin Receptor Type 2 Expressing Neuroendocrine Tumors At ESMO Congress 2026
- Perspective's [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs
- Perspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Patients With Locally Advanced Unresectable And/Or Metastatic Fibroblast Activation Protein-Positive Solitary Fibrous Tumors
- Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
- Perspective Therapeutics (NYSEAMERICAN:CATX) Given “Buy” Rating at BTIG Research
- BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target
- Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium
- Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Stock Now Rated “Buy” by Sell-Side Analysts
Your note
Sign in to keep a note on CATX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AUSTIN MARK JOHN | Chief Financial Officer | Conversion of Exercise of derivative security | Apr 22, 2024 | 84,030 |
| HENSON HEIDI | Director | Purchase | Dec 3, 2024 | 0 |
| HUNT JONATHAN ROBERT | Chief Financial Officer | Purchase | Nov 24, 2024 | 48,800 |
| LANTHEUS ALPHA THERAPY, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Mar 5, 2024 | 0 |
| PUHLMANN MARKUS | Officer | Purchase | Jan 23, 2024 | 1,375,420 |
| SPOOR JOHAN M | Chief Executive Officer | Purchase | Dec 3, 2024 | 55,257 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 8.14% | 5,504,822 | 17.29M | Sep 29, 2024 |
| Janus Henderson Group PLC | 7.10% | 4,799,352 | 15.07M | Sep 29, 2024 |
| Blackrock Inc. | 5.98% | 4,039,974 | 12.69M | Sep 29, 2024 |
| Avidity Partners Management, LP | 5.10% | 3,444,002 | 10.81M | Sep 29, 2024 |
| Commodore Capital Lp | 4.96% | 3,350,000 | 10.52M | Sep 29, 2024 |
| Vanguard Group Inc | 4.55% | 3,076,941 | 9.66M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.50% | 1,692,046 | 5.31M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.06% | 1,393,938 | 4.38M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.72% | 1,162,536 | 3.65M | Sep 29, 2024 |
| Fidelity Advisor Biotechnology Fund | 1.56% | 1,052,713 | 3.31M | Oct 30, 2024 |
| Janus Henderson Global Life Sciences Fund | 1.41% | 953,832 | 3.00M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.19% | 806,419 | 2.53M | Sep 29, 2024 |